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Background: Several studies have been published that investigated potential links 
between transcriptome changes and psoriasis using microarrays and RNA-seq tech-
nologies, but no previous study has analyzed expression profile of alternatively spliced 
transcripts in psoriasis.
Objectives: Identification of potential alternatively spliced RNA isoforms with dis-
ease-specific expression profile.
Methods: Using our published RNA sequencing data from lesional psoriatic (LP), 
non-lesional psoriatic (NLP), and normal control skin (C), we analyzed the differential 
expression of RNA splicing variants. LP sample was compared with NLP, as was LP with 
C and NLP with C.
results: Transcript-based annotation analyzed 173,446 transcripts (RNA isoforms), 
and around 9,000 transcripts were identified as differentially expressed between study 
groups. Several previously undescribed RNA variants were found. For instance, tran-
script ETV3_3 (ENST00000326786) was significantly downregulated in LP and NLP skin. 
ETV3 is a transcriptional repressor that contributes to the downstream anti-inflammatory 
effects of IL-10. We also identified diseases-specific transcripts (S100A7A, IL36RN_4, 
and IL36G_3) of genes already recognized to be involved in inflammation and immune 
response.
conclusion: Psoriasis is characterized by significant differences in the expression of 
RNA alternative isoforms. Description of these new isoforms improves our knowledge 
about this complex disease.
Keywords: psoriasis, transcriptome, transcript expression profiling, rna sequencing
inTrODUcTiOn
Psoriasis is one of the most prevalent chronic inflammatory diseases that affect the skin and 
joints (1). The disease affects 2–3% of the worldwide population, although the clinical course and 
severity varies (2). The cause of psoriasis is unknown; it is a complex disease with multifactorial 
pathogenesis where several genes interact and eventually induce the active disease (3–5).
TaBle 1 | characteristics of the psoriasis patients.
Patient age in  
years
gender aoO  
(years)
Pasi nail  
involvement
Psa
1 19 M 18 (0.5) 12.5 No No
2 25 M 13 (12) 18.4 Yes No
3 27 M 18 (9) 8.8 No No
4 29 M 26 (3) 3.7 No No
5 49 M 15 (34) 6.0 No No
6 52 M 22 (30) 14.0 Yes No
7 60 M 56 (4) 10.8 No No
8 28 F 28 (0.5) 23.3 No No
9 37 F 30 (7) 4.7 No No
10 54 F 14 (40) 7.3 No Yes
11 57 F 53 (4) 12.6 No No
12 58 F 57 (1) 15.2 No No
AoO, age of onset; M, male; F, female; PASI, Psoriasis Area and Severity Index; PsA, 
psoriatic arthritis.
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Studies of the psoriatic gene expression profiles using microar-
rays and RNA-seq technologies have revealed large number of 
differentially expressed genes (DEGs) in lesional skin (6–12). 
More than 1,000 differentially regulated genes have been found 
for psoriatic compared to non-psoriatic skin using microarrays 
(7, 8). These studies have resulted in identification of new gene 
candidates regarding the pathogenesis of psoriasis. Around 80% 
of significantly elevated genes in psoriasis lesions are related to 
keratinocyte activity and infiltration by T-cells and macrophages 
(10). In addition to GeneChips, recent data from RNA-seq provide 
a more comprehensive overview of the transcriptional landscape 
of psoriasis. RNA-seq is able to detect transcripts and splicing 
forms undetectable with other tools (13). Transcriptome-based 
classification is able to discriminate subgroups of psoriasis with 
different molecular patterns (14). Several RNA-seq based studies 
on psoriasis have been published to date (11, 12, 15). All these 
studies described some previously undiscovered RNAs involved 
in psoriasis, supporting the power of RNA-seq to discover novel 
genes. In one study, three pairs of lesional and normal skin 
samples from psoriatic individuals were analyzed (15). Li et al. 
(11) found 3,577 DEGs between lesional and normal skin using 
biopsies from 92 psoriatic patients and 82 normal individuals. 
In a recent study, we performed RNA-seq-based gene expression 
profiling on 12 paired lesional (LP) and non-lesional (NLP) skin 
samples from psoriatic individuals and 12 skin samples from 
controls (C) (12). Besides other well-known genes, we identified 
robust expression of IL36 cytokines to be involved in the clinical 
development of psoriasis.
Most of these earlier studies focused only on gene-level anno-
tation and as a result, transcript-specific information was never 
used. In one study however, exon-specific differential analysis was 
applied and 343 differentially used exons in lesional skin were 
discovered compared to controls (11). This finding suggests that 
transcript-based annotation should show new RNA isoforms in 
psoriatic lesional samples.
In the present study, we reanalyzed our previously published 
RNA-seq data (12) using transcript-based annotation to find 
alternatively spliced RNAs specific to psoriatic skin. We analyzed 
173,446 different annotated RNA isoforms in the skin in relation 
to the existence of psoriatic lesion.
MaTerials anD MeThODs
Patients and controls
The Ethics Review Committee on Human Research of the 
University of Tartu approved the protocols and informed consent 
forms used in this study. All the study procedures conformed to 
the relevant regulatory standards. All the participants signed an 
informed consent form. The patients (N = 12) and control subjects 
(N =  12) were unrelated Caucasians living in Estonia. Patients 
from the Department of Dermatology of Tartu University Hospital 
with plaque psoriasis constituted the former group. Gender- and 
age-matched (±10 years) control subjects were recruited at the 
dermatologic outpatient clinic among patients with melanocytic 
nevi. These controls were free from inflammatory dermatoses and 
had no family history of psoriasis. The main characteristics of the 
psoriasis patients are presented in Table 1.
rna sequencing
The DNA fragment library was prepared using SOLiD System 
chemistry (Life Technologies Corp., Carlsbad, CA, USA). Also, 
50 ng of total RNA was amplified using Ovation RNA-Seq System 
V2 (NuGen, Emeryville, CA, USA). Sequencing was performed 
using SOLiD 5,500 W. Also, 75 bp from the forward primer was 
sequenced, and on average 20 million reads per sample were 
received. Raw reads were mapped to the human genome hg19 
reference, using CLC Genomic Workbench (Qiagen, Germany) 
software. The CLC Genomic Workbench identified a total of 
173,446 transcripts, which were then used for downstream 
analysis.
Quantitative real-Time Pcr
cDNA synthesis was performed on 250  ng of total RNA 
using a High Capacity RNA-to-cDNA Kit (Life Technologies 
Corp.). A QuantiTect Reverse Transcription Kit (Qiagen) 
was applied for cDNA synthesis in the case of g1 and s1 
assays. Both cDNA synthesis kits were used according to the 
manufacturer’s protocol. cDNA was used as a template for 
TaqMan qRT-PCR using the 7900 Fast QRT-PCR System (Life 
Technologies Corp.). Two primers and a labeled probe were 
used to detect the mRNA expression level of the reference 
gene hypoxanthine phosphoribosyl-transferase-1 (HPRT-1; 
primer sequences available upon request). Expression levels 
of ETV3_3, S100A7A_2, IL36RN_4, and IL36G_3 were detected 
using TaqMan Gene Expression Assays (Life Technologies 
Corp.) Hs02786659_s1, Hs00752780_s1, Hs01104217_g1, and 
Hs00922858_m1, respectively. These assays were specific for 
the mentioned RNA isoforms and detected selectively only 
one isoform out of several variants. The assay specificity to 
detect alternative isoforms is illustrated in Figures S7–S10 in 
Supplementary Material. We selected genes for the qRT-PCR 
confirmation based on their statistical significance (ETV3 
and S100A7A_2) from two different comparisons (LP–C and 
LP–NLP). IL36RN_4 and IL36G_3 were selected because these 
genes are recently identified targets in the pathogenesis of 
psoriasis, and it was important to analyze the expression of 
different isoforms. The gene expression levels from qRT-PCR 
TaBle 2 | analysis of transcript isoforms in psoriasis, lP–c comparison, sorted by FDr value.
Transcripts logFc logcPM p-value FDr enseMBl iD gene name
ETV3_3 −4.12 7.41 8.29E−173 2.13E−168 ENST00000326786 Ets variant 3
NLK_6 −2.35 6.84 2.84E−90 3.65E−86 ENST00000407008 Nemo-like kinase
PLA2G4D_2 4.28 5.42 1.54E−66 1.32E−62 ENST00000290472 Phospholipase A2, group IVD (cytosolic)
TGM1_4 3.95 6.35 2.19E−54 1.41E−50 ENST00000206765 Transglutaminase 1
IL36RN_4 4.19 7.21 2.02E−51 1.04E−47 ENST00000393200 Interleukin 36 receptor antagonist
C0PG1_2 −2.68 4.28 4.32E−51 1.85E−47 ENST00000512034 Coatomer protein complex, subunit gamma 1
ALOX12B_2 2.96 7.24 2.64E−50 9.69E−47 ENST00000319144 Arachidonate 12-lipoxygenase, 12R type
SAMD9_1 2.94 6.16 5.35E−50 1.72E−46 ENST00000379958 Sterile alpha motif domain containing 9-like
STAT1_4 2.41 7.82 5,19E−49 1.48E−45 ENST00000361099 Signal transducer and activator of transcription 1.91 kDa
CRABP2_2 2.84 5.54 4.52E−46 1.16E−42 ENST00000368222 Cellular retinoic acid-binding protein 2
CNFN_2 3.71 6.67 1.90E−45 4.44E−42 ENST00000222032 Cornifelin
VARS_11 −3.50 4.58 2.07E−44 4.43E−41 ENST00000461328 Valyl-tRNA synthetase
KRT6A_2 4.50 11.56 2.67E−44 5.28E−41 ENST00000330722 Keratin 6A
CD300E_3 2.70 4.58 6.60E−44 1.21E−40 ENST00000392619 CD300e molecule
SOX5_16 −2.86 5.40 2.04E−42 3.49E−39 ENST00000546136 SRY (sex determining region Y)-box 5
SPTLC2_2 1.32 7.79 2.66E−42 4.27E−39 ENST00000216484 Serine palmitoyltransferase, long chain base subunit 2
TGM3_1 3.38 7.46 8.24E−42 1.25E−38 ENST00000381458 Transglutaminase 3
GLTP_5 2.02 7.68 8.90E−42 1.27E−38 ENST00000318348 Glycolipid transfer protein
FABP5_3 4.38 6.16 1.44E−41 1.95E−38 ENST00000481695 Fatty acid-binding protein 5 (psoriasis-associated)
LYZ_1 3.05 6.50 4.50E−41 5.79E−38 ENST00000261267 Asparagine synthetase (glutamine-hydrolyzing)
IL36G_3 5.43 6.53 5.41E−40 6.62E−37 ENST00000259205 Interleukin 36, gamma
HERC6_3 4.31 5.99 1.56E−39 1.83E−36 ENST00000264346 HECT and RLD domain containing E3 ubiquitin protein 
ligase family member 6
CLSTN2_1 −2.05 5.74 1.51E−38 1.68E−35 ENST00000458420 Calsyntenin 2
PGAM1_1 2.04 6.40 7.24E−38 7.76E−35 ENST00000334828 Phosphoglycerate mutase 1 (brain)
KRT16_2 4.73 8.10 1.27E−37 1.31E−34 ENST00000301653 Keratin 16
Differentially expressed transcripts in psoriatic lesions compared to control skin (LP–C). LogFC is fold-change differences on the log2 scale and describes how many times gene 
expression differs between groups. Positive values indicate gene upregulation in psoriasis patients. Log2 counts per million (LogCPM) is the average gene expression signal of all 
samples. FDR is a genome-wide corrected p-value.
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were calculated relative to the reference gene HPRT-1 using 
the 2-ΔCT method. A paired t-test was used to evaluate any 
statistical significance between expressions.
statistical analysis
We filtered out transcripts with low-expression level and did not 
use them in any further analysis. The EdgeR statistical package 
was used to analyze the non-normalized raw RNA isoform counts 
to find differential gene expressions. EdgeR performs model-
based normalization, estimates dispersions, and applies a nega-
tive binomial model. EdgeR is a very flexible tool for RNA-seq 
data analysis for finding DEGs (16, 17). It fits a negative binomial 
model and then tests the procedures for determining differential 
expression.
We used a group comparison for samples of LP and NLP with 
C, and a paired comparison for LP and NLP. False discovery rate 
(FDR) adjustment was used for multiple testing corrections (18, 
19). Our sample size of 12 patients provides sufficient power to 
find DEGs (20, 21).
resUlTs
rna sequencing results
We performed three comparisons: LP–C, NLP–C, and L–NLP. Of 
the 173,446 transcripts analyzed, 25,724 were expressed in all 36 
samples at a ≥1 cpm (counts per million) level. In general, only 
one or two alternative isoforms of transcripts were expressed. 
In case of some genes, several different transcripts were expressed 
at the same time (e.g., SERPINB4).
Figure S1 in Supplementary Material is a multidimensional 
scaling (MSD) plot that shows clear separation of the LP, NLP, 
and C samples. When differences between the LP and C samples 
were analyzed, 8,694 transcripts were differentially expressed at 
an FDR-corrected statistical significance level of 0.05. Table  2 
provides the 25 most significant differentially expressed tran-
scripts. The transcripts with the lowest FDR values also had the 
largest absolute logFC values, which indicate large expressional 
differences between samples. A heatmap (Figure  1) showed 
that the differences found should be considered consistent and 
characteristic of our study groups. The Volcano- and MA-plots 
on Figures S2 and S3 in Supplementary Material show reciprocal 
associations between logFC and FDR and gene expression level 
in our study sample.
The most significantly downregulated transcript in the LP 
sample was ETV3_3, followed by NLK_6, a nemo-like kinase. 
Most of the transcripts that were significantly upregulated in the 
LP sample are known to be related to the activation of immune 
functions. PLA2G4D, TGM1, and IL36RN are all described to 
be involved in the psoriasis (11, 12). IL36RN is quite recently 
identified to have substantial role in different inflammatory skin 
diseases (22). A box plot of the differential expression levels of 
selected transcripts is illustrated in Figure 2.
When we compared NLP skin samples with C samples, the 
most significantly downregulated transcripts in NLP skin (like in 
FigUre 1 | heatmap of the rna-seq expression data for the 50 transcripts with the smallest FDr values (lP–c comparison) illustrating differences 
in transcriptional profiles. The violet bar denotes non-lesional skin samples, the green bar controls, and the red bar lesional samples.
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LP skin) were ETV3_3 and NLK_6 (see Table S2 in Supplementary 
Material). Expression levels of the 50 most differentially expressed 
transcripts (NLP–C) are illustrated in the heatmap Figure S4 in 
Supplementary Material.
And finally, we performed a pairwise comparison of lesional 
(LP) and non-lesional (NLP) samples to identify the transcripts 
that are involved in generation of active lesion (Table S3 in 
Supplementary Material). The most upregulated (the highest 
logFC) transcripts of LP were S100A7A_2, S100A8_2, S100A7_1, 
and KLK10_4. S100A7A_2 corresponds to the long isoform (pre-
viously described as S100A15_L) of S100A15 or S100A7A that 
was identified long time ago (23). This long isoform is identified 
to be specific for lesional psoriatic skin, and our present results 
support this finding (24).
Expression profiles of the 100 most significantly differ-
ent genes are illustrated using a heatmap (see Figure S5 in 
FigUre 2 | Box plots illustrating some of the most differentially expressed transcripts between the lP and c samples. ETV3_3 and NLK_6 were highly 
expressed in control skin but downregulated in lesional and non-lesional skin. The other genes in the figures were all upregulated in the psoriatic samples, but less 
so in non-lesional skin. Abbreviations in the X-axis are LP, lesional, NLP, non-lesional, and C, control.
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Supplementary Material). The box plot of the expression levels of 
selected genes from LP–NLP comparison is illustrated in Figure 
S6 in Supplementary Material. In addition to the transcripts 
found also in other comparisons (IL36RN), specific transcripts 
of S100A8, MPZL2, KLK10, and EHF genes were identified in 
relation to active lesion in the skin. In case of EHF, the transcript 
EHF_12 (ENST00000257831) corresponds to the longest RNA 
variant, but it is not coding the longest protein of all 100 EHF 
variants. Interestingly, these transcripts interact with the psoriasis 
response element motif and are necessary in the development of 
psoriasis (25). EHF is an “ets homologous factor” and distantly 
related to the ETV3 gene that was downregulated in the LP and 
NLP skin samples compared to the controls.
Validation of rna-seq results with 
Quantitative real-Time Pcr
In order to confirm the RNA-seq results, we measured the levels 
of ETV3_3, S100A7A_2, IL36RN_4, and IL36G_3 using real-time 
PCR for the paired LP–NLP samples. All RT-PCR assays were 
selected so that they only detected singe specific RNA isoforms 
and no other RNA isoforms encoded by the same gene. RT-PCR 
analysis confirmed significant differences in the expression of 
gene isoforms between the LP and NLP samples (Figure 3).
DiscUssiOn
In the present study, we present the differences in alternative 
splicing for lesional (LP) and non-lesional (NLP) psoriasis skin 
samples compared to control (C) skin samples. We reanalyzed 
our published data by applying transcript-based annotation (12). 
This annotation enabled analysis of 173,446 transcripts in the 
human genome to find differentially regulated RNA isoforms.
In one previous study, exon-specific differential expression 
in psoriasis samples was analyzed (11). The authors found 343 
exons differentially used between lesional and control skin 
samples (11). Unfortunately, the results were presented only 
in a descriptive table with no formal comparison of lesional to 
NLP skin. Comparison of our results with published Li et al. (11) 
results could therefore be only limited. Mentioned previous study 
indicated differential exon usage for IL1F5 (IL36RN) and IL1F7 
(IL37) genes (11). In present study, we found that the same genes 
and their specific RNA variants are differentially expressed in 
psoriasis samples. Therefore, in general, our results fit well with 
the findings of the Li et al. Our results even extend their find-
ings, and we identified novel RNA isoforms that are differentially 
expressed. Some discrepancies between Li et al. and our findings 
come form different approach. Li et al. used differential exon usage 
FigUre 3 | rT-Pcr results for four different rna isoforms (a–D) and a comparison between paired lP and nlP samples. RNA levels of individual genes 
(a–D are ETV3_3, S100A7A_2, IL36RN_4 and IL36G_3) are expressed relative level to the housekeeper gene. Statistical significance for the paired t-tests is 
designated as *, a p-value less than 0.05 and ***, a p-value less than 0.001.
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analysis that is implemented in the DEXseq package. This analysis 
detects the exons that are differentially expressed but is not able 
to find the exact specific RNA isoforms. As a result, they found 
that 343 exons from 292 genes were differentially expressed (11). 
Our approach resulted in more than 8,000 differentially expressed 
transcripts between LP and C skin. In order to verify our findings, 
we downloaded the original data used in the study of Li et  al. 
and applied our approach. Indeed, our approach found more than 
10,000 transcripts differentially expressed between psoriasis and 
control samples. Moreover, we confirmed differential expression 
for the RNA isoforms for ETV3, IL36G, PLA2G4D, and S100A7A 
with RT-PCR. Taken together, our approach is applicable for 
different datasets and gives consistent findings in our and in the 
previously published datasets.
The most significant differentially expressed transcript 
between LP and C was ETV3_3 (ENST00000326786, see Figure 
S7 in Supplementary Material ETV3-001). Interestingly, the 
most significant differentially expressed transcript is not the 
longest. It is 1,539  bp in length and encodes 143  aa proteins. 
The ETV3 has two additional transcripts, ENST00000368192 
and ENST00000460850. ENST00000368192 is 5,254  bp long 
and encodes protein with 512  aa. ENST00000460850 was the 
shortest (696 bp in length) and is a non-coding transcript. Both 
ENST00000368192 and ENST00000460850 were expressed in 
the skin samples, but their expression did not differ between the 
experimental groups. Therefore, ETV3_3 seems to be specific to 
psoriasis, and its downregulation in LP samples was remarkable 
(logFC −4.06). In the case of NLK_6 (ENST00000407008), it is 
the one splicing variant out of six existing variants of NLK gene 
and encodes the 527  aa protein. In addition to NLK_6, only 
NLK_2 (ENST00000582037) of all the NLK isoforms was differ-
entially expressed (FDR value below 0.05). NLK_2 encodes the 
181 aa protein of the NLK gene. Both ETV3_3 and NLK_6 were 
downregulated in the LP sample. The ETV3 gene functions as a 
component of the IL-10-regulated pathway that represses inflam-
matory response (26). IL-10 and the IL-10 family of cytokines 
are involved in genetic susceptibility to psoriasis vulgaris and 
palmoplantar pustulosis (27, 28). Therefore, ETV3 seems to be a 
good candidate for regulating psoriasis inflammation. ETV3 was 
initially discovered as an ETS family repressor of gene expression 
in macrophage development (29). The second most significantly 
downregulated transcript in the LP sample was NLK_6. NLK is 
also related to immune suppression, and it negatively regulates 
NF-kappaB (30). However, our RT-PCR experiment did not 
verify the differential expression of NLK_6 isoform, but this 
transcript still remains interesting candidate.
A comparison between LP and NLP samples should 
describe the lesion-specific changes induced by the active 
inflammation in the skin. Two splicing variants of S100A8 
(ENST00000368733 and ENST00000368732), one variant of 
S100A7A (ENST00000368729), and one variant of S100A7 
(ENST00000368723) were significantly upregulated in lesional 
7Kõks et al. Alternative Splicing in Psoriasis
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skin with very high logFC values. In case of these genes, out of 
two or three existing transcripts for these genes were specifically 
changed. S100A7A_2 corresponds to the long isoform (previously 
described as S100A15_L) of S100A15 or S100A7A gene that was 
cloned and identified in an earlier study (23). Interestingly, this 
long isoform was found to be specific to lesional psoriatic skin 
and therefore supports our finding of lesional – specificity (24). 
Moreover, TNF-α, IFN-γ, and IL-1β have shown to stimulate 
only long isoform (24). We found that S100A15_L (S100A7A_2) 
is slightly upregulated in non-lesional skin (compared to control) 
and is highly upregulated in lesional skin. Skin does not normally 
express the S100A7A long isoform at all and only slightly expresses 
the S100A7A short isoform (23). Therefore, S100A7A is perfect 
example for the transcript-specific regulation of inflammation 
and disease progression. In addition, S100A8 is also a well-
described and well-known psoriasis-inducing gene (31). There 
is evidence that S100A8 binds to unsaturated fatty acids (32). 
Supportive to this interaction was up-regulation of the fatty acid-
binding protein FABP5 in our samples. FABP5 gene has also been 
related to psoriasis (33). Finally, the IL36RN_4 splicing variant of 
the IL36RN gene was similarly upregulated in the lesional sample. 
Therefore, our findings from the lesional to non-lesional skin 
sample comparison coincide with several previous studies. All 
the splicing variants and respective detection assays for RT-PCR 
are illustrated in the Figures S7–S10 in Supplementary Material. 
As seen in the figure, assays were specific for the splicing variants.
In conclusion, our approach in analyzing the specific pattern 
of splicing variants produced some new candidates for the patho-
genesis of psoriasis and indicated transcript-specific regulation. 
Downregulation of ETV3 in psoriatic skin (lesional and non-
lesional) indicates a suppression of anti-inflammatory signals 
for psoriasis. We confirmed the finding of a previous study by 
detecting the up-regulation of S100A7A long isoform in lesional 
skin (24). RNA-seq analysis, where specific transcript splicing 
variants are analyzed, provides substantial additional informa-
tion compared to regular gene-based analysis where signals from 
different transcripts are combined.
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FigUre s1 | Multidimensional scaling plot of the original data indicating 
a clear separation of the experimental groups non-lesional psoriatic skin 
(nlP) and lesional psoriatic skin (lP) with controls (c).
FigUre s2 | Volcano plot shows the relationships between p-values 
(−log 10) and fold-change differences (log 2). The transcripts from the LP–C 
comparison are illustrated.
FigUre s3 | Ma-plot of the transcripts used for the lP–c comparison. 
Transcripts with larger expressional levels had larger fold-change differences.
FigUre s4 | heatmap showing the expression of 50 of the most 
differentially expressed transcripts between the non-lesional and control 
samples. Data from all three groups are illustrated, and it was evident that some 
genes overlap with lesional samples and some with control samples. Transcripts 
common in both LP and NLP samples indicate that even in the non-lesional skin 
of psoriatic patients, the pathogenetic transcripts are active. The violet bar 
denotes controls, the green bar lesional skin samples, and the red bar 
non-lesional samples.
FigUre s5 | heatmap showing the expression of 100 of the most 
differentially expressed transcripts between the non-lesional and lesional 
samples. The green bar denotes non-lesional skin samples and the red bar 
lesional samples.
FigUre s6 | Box plots illustrating some of the most differentially 
expressed transcripts between the lP and nlP samples. Abbreviations in 
the X-axis are LP, lesional; NLP, non-lesional.
FigUre s7 | This figure illustrates the different transcripts for the eTV3 
gene and the position of the TaqMan assay (red box). ETV3_001 was the 
transcript found to be specifically downregulated in the case of psoriasis.
FigUre s8 | This figure illustrates the different transcripts for the 
s100a7a gene and the position of the TaqMan assay (red box). S100A7A 
001 was the transcript found to be specifically downregulated in the case of 
psoriasis.
FigUre s9 | This figure illustrates the different transcripts for the il36rn 
gene and the position of the TaqMan assay (red box). IL36RN _001 was the 
transcript found to be specifically downregulated in the case of psoriasis.
FigUre s10 | This figure illustrates the different transcripts for the il36g 
gene and the position of the TaqMan assay (red box). IL36G _001 was the 
transcript found to be specifically downregulated in the case of psoriasis.
TaBle s1 | Differentially expressed transcripts in lesional skin compared 
to controls (lP–c). Data are sorted descending in terms of absolute logFC 
values.
TaBle s2 | Differentially expressed transcripts in non-lesional skin 
compared to controls (nlP–c). Data are sorted descending in terms of 
absolute logFC values.
TaBle s3 | Differentially expressed transcripts in lesional skin compared 
to non-lesional skin (lP–nlP).
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